BRAFV600E与MEK联合阻断治疗BRAFV600E突变胶质瘤
本文研究胶质瘤中BRAFV600E抑制剂内在耐药的分子机制,并探讨BRAFV600E/MEK联合治疗能否克服耐药并预防继发性恶性肿瘤。结果显示BRAFV600E抑制后ERK磷酸化恢复,联合MEK抑制可阻止MAPK信号再激活,增强抗肿瘤效果并减少继发性恶性肿瘤风险。
要点
- BRAFV600E抑制后ERK磷酸化恢复,导致胶质瘤内在耐药。
- 联合BRAFV600E和MEK抑制可阻止MAPK信号再激活,增强抗肿瘤效果。
- 联合治疗还可减少继发性恶性肿瘤(如皮肤鳞状细胞癌)的发生风险。
核心结论
- 在胶质瘤中,BRAF抑制后MAPK信号恢复导致对BRAFV600E抑制剂的内在耐药。
- 联合BRAFV600E和MEK抑制可阻止MAPK激活反弹,增强抗肿瘤疗效并降低继发性恶性肿瘤发生风险。
研究设计与样本
- 采用免疫印迹和人磷酸化受体酪氨酸激酶阵列检测MAPK通路激活。
- 通过WST-1活力 assay 和细胞周期分析确定BRAFV600E和MEK抑制的细胞效应。
- 使用 flanked 和原位GBM小鼠模型研究BRAFV600E/MEK联合治疗的体内疗效及对继发性恶性肿瘤的影响。
主要发现
- BRAFV600E抑制导致ERK磷酸化恢复。
- 联合BRAFV600E和MEK抑制阻止MAPK信号再激活,与细胞活力降低和细胞周期阻滞增强相关。
- 在BRAFV600E胶质瘤小鼠中,与单用BRAFV600E抑制相比,联合BRAFV600E和MEK抑制剂治疗显示肿瘤生长减少。
- 联合BRAFV600E/MEK抑制的额外获益体现为皮肤鳞状细胞癌(cSCC)生长减少(作为RAS驱动继发性恶性肿瘤的替代指标)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAFV600E is a common finding in glioma (about 10-60% depending on histopathologic subclassification). BRAFV600E monotherapy shows modest preclinical efficacy against BRAFV600E gliomas and also induces adverse secondary skin malignancies. Here, we examine the molecular mechanism of intrinsic resistance to BRAFV600E inhibition in glioma. Furthermore, we investigate BRAFV600E/MEK combination therapy that overcomes intrinsic resistance to BRAFV600E inhibitor and also prevents BRAFV600E inhibitor induced secondary malignancies. Immunoblotting and Human Phospho-Receptor Tyrosine Kinase Array assays were used to interrogate MAPK pathway activation. The cellular effect of BRAFV600E and MEK inhibition was determined by WST-1 viability assay and cell cycle analysis. Flanked and orthotopic GBM mouse models were used to investigate the in vivo efficacy of BRAFV600E/MEK combination therapy and the effect on secondary malignancies. BRAFV600E inhibition leads to recovery of ERK phosphorylation. Combined BRAFV600E and MEK inhibition prevents reactivation of the MAPK signaling, which correlates with decreased cell viability and augmented cell cycle arrest. Similarly, mice bearing BRAFV600E glioma showed reduced tumor growth when treated with a combination of BRAFV600E and MEK inhibitor compared to BRAFV600E inhibition alone. Additional benefit of BRAFV600E/MEK inhibition was reflected by reduced cutaneous squamous-cell carcinoma (cSCC) growth (a surrogate for RAS-driven secondary maligancies). In glioma, recovery of MAPK signaling upon BRAF inhibition accounts for intrinsic resistance to BRAFV600E inhibitor. Combined BRAFV600E and MEK inhibition prevents rebound of MAPK activation, resulting in enhanced antitumor efficacy and also reduces the risk of secondary malignancy development.
引用
- Zhang J, Yao TW, Hashizume R, et al. Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol. 2016. PMID: 27848137. doi:10.1007/s11060-016-2333-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。